DEF: Atossa Seeks Reverse Stock Split to Maintain Nasdaq Listing

Atossa Therapeutics, Inc. will hold a Special Meeting on January 20, 2026, to seek stockholder approval for a reverse stock split to regain compliance with Nasdaq's minimum bid price rule and avoid delisting.

Summary

• Atossa Therapeutics, Inc. is holding a Special Meeting of Stockholders on January 20, 2026, to vote on two proposals.
• The primary proposal (Proposal 1) is to approve an amendment to the Certificate of Incorporation to effect a reverse stock split of common stock at a ratio ranging from 5:1 to 20:1.
• The purpose of the reverse stock split is to increase the per share trading price of the common stock to maintain the company's listing on the Nasdaq Stock Market.
• The company received a Nasdaq notification on February 21, 2025, for non-compliance with the minimum bid price rule ($1.00 per share).
• An extension was granted until February 17, 2026, to regain compliance; however, the company failed to maintain the $1.00 bid price for the required consecutive business days in October 2025 after Nasdaq exercised its discretion for extended monitoring.
• As of December 19, 2025, the closing price of the common stock was $0.73 per share.
• The Board of Directors unanimously recommends voting FOR both Proposal 1 and Proposal 2 (adjournment, if necessary).
• Proposal 2 seeks approval to adjourn the Special Meeting, if necessary, to solicit additional proxies.
• The reverse stock split would affect all stockholders uniformly, with proportionate adjustments to stock options and convertible preferred stock, and cash paid in lieu of fractional shares.
• The Board retains the sole option to implement the reverse stock split and determine the exact ratio within the approved range after stockholder approval.

Sentiment

Score: 3

Explanation: The filing addresses a critical issue (Nasdaq delisting) with a proposed solution (reverse stock split). While the solution is necessary, the underlying problem of low stock price and failure to maintain compliance is a significant negative. The risks associated with the reverse split itself, such as no guarantee of success and potential for further price decline, contribute to a low sentiment score. The management change (CFO stepping down) also adds a layer of uncertainty.

Positives

• The proposed reverse stock split aims to maintain the company's Nasdaq listing, which is crucial for financing, trading liquidity, and investor confidence.
• An increased stock price could improve marketability and liquidity, potentially attracting institutional investors and reducing transaction costs for individual investors.
• The Board believes a higher stock price may reduce the risk of market manipulation and decrease stock price volatility.
• The reverse stock split would increase the number of authorized but unissued shares, providing flexibility for future capital raises, debt repurchases, equity incentives, and acquisitions.

Negatives

• The company is currently non-compliant with Nasdaq's minimum bid price rule, with a closing price of $0.73 per share as of December 19, 2025, and faces potential delisting by February 17, 2026.
• There is no assurance that the reverse stock split will sufficiently increase the stock price to regain compliance or be completed before delisting procedures begin.
• The stock price after a reverse stock split may not increase proportionally, potentially leading to a reduction in the company's overall market capitalization.
• The stock price may still decline due to various factors, including future performance and general market conditions, potentially at a greater rate than without a split.
• A reverse stock split may decrease the liquidity of the common stock due to a reduced number of outstanding shares and could result in higher transaction costs for stockholders owning odd lots.
• The effective increase in authorized shares could have anti-takeover implications, potentially deterring changes in control.
• Some investors may view a reverse stock split negatively.

Risks

• Delisting from Nasdaq: The company faces delisting if it does not regain compliance with the Bid Price Rule by February 17, 2026. Delisting would adversely affect financing, trading ability, value, and liquidity of common stock.
• Uncertainty of Reverse Stock Split Effectiveness: There is no guarantee the reverse stock split will sufficiently increase the stock price to regain compliance or be completed before delisting.
• Disproportionate Stock Price Increase: The stock price after a reverse stock split may not increase in the same proportion as the reduction in shares, potentially reducing overall market capitalization.
• Continued Stock Price Decline: Even after a reverse stock split, the stock price may decline due to company performance, industry, market, or economic conditions.
• Decreased Liquidity and Higher Transaction Costs: A reduced number of outstanding shares post-split could decrease liquidity, and an increase in odd lots (fewer than 100 shares) could lead to higher transaction costs for stockholders.
• Anti-Takeover Implications: The increase in authorized but unissued shares resulting from the split could be used to oppose hostile takeover attempts or delay changes in control.

Future Outlook

The company anticipates that a successful reverse stock split will enable it to regain compliance with Nasdaq's minimum bid price rule, thereby maintaining its listing. This action is also expected to improve the marketability and liquidity of its common stock, potentially reduce market manipulation risk, and provide greater flexibility for future capital raising and business expansion. However, there is no assurance that the stock price will increase proportionally or that compliance will be regained before the delisting deadline.

Management Comments

• "After careful consideration, our Board of Directors has unanimously approved the proposals and recommends that you vote FOR Proposals 1 and 2."
• "The Board believes that delisting from Nasdaq would adversely affect the Company's ability to raise additional financing through the public or private sale of equity securities, would significantly affect the ability of investors to trade in the Company's securities and would negatively affect the value and liquidity of the Company's common stock."
• "The Board believes that an increased stock price may also improve the marketability and liquidity of our common stock."
• "The Board believes that the potential increase in stock price may reduce the risk of market manipulation of our common stock, which we believe is enhanced when our stock trades below $1.00 per share."
• "We currently do not have any specific plans, arrangements, understandings or commitments for the additional shares that would become available [from the reverse stock split]."

Industry Context

The need for a reverse stock split to maintain Nasdaq listing is a common challenge for smaller biotechnology or development-stage companies whose stock prices may fluctuate significantly due to clinical trial results, regulatory milestones, or market sentiment. Maintaining a Nasdaq listing is critical for these companies to attract institutional investment, access capital markets, and ensure liquidity for existing shareholders, as many funds and brokers have policies against investing in or recommending 'penny stocks'.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to assess the company's performance against global benchmarks. However, the situation of a company facing delisting due to a low bid price and proposing a reverse stock split is a common occurrence among smaller-cap companies, particularly in the biotechnology sector, that struggle to maintain investor interest or achieve significant market milestones.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Will own fewer shares but with a proportionally higher per-share price. Fractional shares will be cashed out. Risk of further price decline and reduced liquidity. Potential benefit of maintaining Nasdaq listing.
• Employees: Potential loss of confidence if delisting occurs. Equity incentives (stock options) will be adjusted proportionally.
• Investors (Institutional): May be more willing to invest if stock price is above certain thresholds, improving marketability.
• Creditors: Maintaining Nasdaq listing can positively impact the company's ability to raise financing, which could indirectly affect creditors' perception of risk.

Next Steps

• Stockholders to register by January 18, 2026, to attend the virtual Special Meeting.
• Stockholders to vote on Proposal 1 (reverse stock split) and Proposal 2 (adjournment) at the Special Meeting on January 20, 2026.
• The Board of Directors will determine whether to implement the reverse stock split and select the specific ratio (between 5:1 and 20:1) after stockholder approval.
• The company will publicly announce the chosen reverse stock split ratio prior to the Effective Date.
• The company must regain compliance with Nasdaq's minimum bid price rule by February 17, 2026, to avoid delisting.

Key Dates

Recommendation

The proposed reverse stock split is a necessary defensive measure to maintain the company's Nasdaq listing, which is critical for its long-term viability and access to capital markets. However, it does not address the underlying issues that led to the low stock price. While avoiding delisting is a positive, the inherent risks of a reverse split (e.g., no guarantee of sustained price increase, potential for further decline, reduced liquidity) and the recent CFO departure introduce significant uncertainty. Investors should hold to see if the reverse split successfully achieves its objective and if the company can demonstrate improved operational performance or strategic developments to justify a higher valuation. A 'buy' would be premature given the risks, and a 'sell' would be an overreaction to a necessary, albeit risky, corporate action.

Keywords

Reverse Stock Split, Nasdaq Listing Compliance, Delisting Risk, ATOS, Proxy Statement, Special Meeting, Stockholder Vote, Corporate Governance, Biotechnology, Pharmaceuticals